comprehensive -WSS

comprehensive

author：fashion 2025-08-22 17:22:43 - browse：28442

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： JPM 2024: Nvidia claims we're in biological revolution. Are we?

WSS

Designating disabled people as health disparity population is crucial

A Greenpeace activist is fined for crash

Heart disease and mental health: A look at cardiac psychology

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

JPM 2024: Verve Therapeutics looks to mainstream genome editing

focus

comprehensive

focus

United colonoscopy coverage change 'may cost lives,' doctors say

A Greenpeace activist is fined for crash

Novavax promises a turnaround & Lilly roils the obesity market

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Drug repurposing or repositioning? The language matters

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

In Memoriam: Notable people who died in 2023

Giant panda gives birth to squirming, squealing healthy twin girls at South Korean theme park

State Dept. review finds Biden bears some blame for Afghanistan failures

Britney Spears to release memoir, 'The Woman In Me,' later this year

explore

A Greenpeace activist is fined for crash

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

GSK to buy asthma

Antibody drugs appear effective. Now can we make enough of them?

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

China sends large group of warplanes, navy ships towards Taiwan in forceful display

leisure time

hotspot

hotspot

explore